Trinity Biotech Reports Prostate Test Study Results Trinity Biotech released clinical study results on Mar 23, 2026 (Investing.com 13:29:08 GMT); full trial metrics and peer-reviewed data are needed to assess commercial outlook.

Trinity Biotech Reports Prostate Test Study Results: Trinity Biotech released clinical study results on Mar 23, 2026 (Investing.com 13:29:08 GMT); full trial metrics and peer-reviewed data are… 👈 Read full analysis #TrinityBiotech #ProstateHealth #ClinicalStudies #Diagnostics #HealthcareInnovation

UK diabetes testing error forces 55,000 patients to retest

Faulty Trinity Biotech HbA1c analysers gave inaccurate results for at least 55,000 patients in England, prompting repeat testing after a July 2025 MHRA notice. Read more: getnews.me/uk-diabetes-testing-erro... #trinitybiotech #diabetes #ukhealth

Trinity Biotech stock rises on successful CGM calibration-free trial Investing.com -- Trinity Biotech plc (NASDAQ:TRIB) stock rose 4.4% following the company’s announcement of positive clinical trial results for its next-generation continuous glucose monitoring (CGM) technology. The biotechnology company reported that its redesigned needle-free glucose sensor successfully delivered accurate glucose readings across a full 15-day wear period without requiring finger-stick calibration. This technical breakthrough represents a significant milestone in the development of Trinity’s CGM+ platform, which aims to reduce costs compared to current market leaders by utilizing a modular design with fewer disposable components. "This milestone represents the most significant technical achievement since we began redevelopment of our acquired CGM technology," said John Gillard, CEO of Trinity Biotech. "The elimination of the requirement for finger-stick calibration was achieved through a combination of sensor design modifications, refined signal processing, and proprietary enhancements to sensor operation." The company’s CGM+ device is designed to integrate multiple health metrics including glucose monitoring, heart activity, body temperature, and physical activity data in a single wearable biosensor. Trinity Biotech is positioning its technology as a more affordable alternative in the growing CGM market, which is projected to expand from approximately $13 billion in 2025 to approximately $28 billion by 2030. The successful trial results address what the company described as "the most uncertain technical hurdle" in its development process, potentially clearing a path toward commercialization and regulatory approval for the CGM+ platform. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. With TRIB making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed TRIB alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including TRIB, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is TRIB poised for similar growth? Don't miss the opportunity to find out.

Click Subscribe #TrinityBiotech #Biotech #StockMarket #Investing #ClinicalTrials

PRISM Mid-Day Movers: FDA Progress and Global Health Approvals Boost Indices
#CapricorTherapeutics Rises 18% on FDA Progress for Duchenne Cell Therapy
#TrinityBiotech Surges 20% Following WHO Approval for HIV Test Manufacturing Shift
prismmarketview.com/prism-mid-da...